TAIPEI, Taiwan — TSH Biopharm Co., Ltd. (TW-8432) attended an institutional investor conference hosted by Ruentex Securities today (27th), hosted by General Manager Szu-Yuan Yang. Benefiting from the robust execution of its "Dual-Engine" strategy and the continuous synergy derived from subsidiary acquisitions, TSH Biopharm delivered full-year 2025 consolidated revenue of NT1.337billion,markinga20218 million, up 29% YoY, while net income attributable to owners of the parent surged by 40% YoY to NT188million.Earningspershare(EPS)reachedNT3.63. Profit growth significantly outpaced top-line expansion, reflecting enhanced operational efficiency and the high-quality execution of strategic initiatives.

Constructing a Comprehensive Healthcare Ecosystem; Subsidiaries Inject Strong Growth Momentum

TSH Biopharm highlighted that the primary growth drivers in 2025 stemmed from steady contributions by core pharmaceuticals alongside comprehensive integration of its newly acquired subsidiaries, Cyun-Yi Biotech and Kaofung Pharmaceutical. The group has successfully built an integrated healthcare ecosystem spanning prevention, diagnostics, and therapy. In the 2025 revenue breakdown:

• Intervention & Therapy (Pharmaceuticals): 58%
• Prevention & Health Maintenance (Vaccines, Dietary Supplements): 37%
• Diagnostics & Monitoring (Testing Services): 4%

 

Both high-growth subsidiaries demonstrated outstanding performance:

• Kaofung Pharmaceutical recorded a 2025 EPS of NT6.09andproposedatotaldividendofNT4.00 per share (comprising NT3.00incashandNT1.00 in stock).
• Cyun-Yi Biotech posted an EPS of NT1.69,achievingaprofitableturnaroundin2025anddeclaringacashdividendofNT1.00 per share for the first time, demonstrating solid shareholder return capabilities post-transformation.

 

Exceeding Drug License Targets Ahead of Schedule; Precision Medicine Recognized with National Quality Accreditations

TSH Biopharm achieved its milestone of "Securing 10 Drug Licenses in 5 Years" ahead of schedule. Currently, 15 pipeline projects remain actively in development (comprising 7 pharmaceuticals, 4 diagnostic tools, and 4 health supplements). In alignment with ESG principles and social responsibility commitments, rare disease therapeutics are slated for sequential market launch in 2026 and 2028. Furthermore, the group's subsidiaries will roll out the "ImmuGuard" series and bone health products next year to continuously penetrate the high-margin, self-pay market.

In the field of precision medicine, TSH Biopharm's liquid biopsy technology was published in top-tier international journals twice in 2025 and received the 28th Symbol of National Quality (SNQ) certification. This proprietary technology successfully utilizes pleural effusion and ascites as diagnostic specimens, enabling non-invasive liquid biopsies. In 2026, the company also introduced two novel breast cancer diagnostic panels, providing stage IV patients with clinically actionable insights for targeted therapy selection.

 

Outlook for 2026: Driven by Four Core Engines toward a High-Margin Growth Phase

General Manager Szu-Yuan Yang emphasized that TSH Biopharm has successfully transformed into a comprehensive healthcare ecosystem group. Looking ahead to 2026, the company will accelerate growth through "Four Core Engines":

1. Developing niche products in ophthalmology and rare diseases
2. Deepening channel penetration across Taiwan
3. Expanding overseas market presence
4. Capitalizing on inorganic growth via mergers and acquisitions (M&A)

 

As the dual-engine strategy bears fruit, revenue from self-pay products is targeted to cross the NT$650 million mark, expanding its revenue contribution from an initial 8% to 50%. This ongoing portfolio optimization will strengthen margin structures, reinforce operational momentum, and drive sustainable, long-term corporate value.